PDF herunterladen
CC BY 4.0 · Arch Plast Surg 2024; 51(05): 487-494
DOI: 10.1055/a-2338-9192
Pediatric/Craniomaxillofacial/Head and Neck
Original Article

Is a 3 mm Surgical Margin Safe for Basal Cell Carcinoma in the Head and Neck that is Less than 2 cm, Considering Different Risk Factors?

Min-Jun Yong 
1   Department of Plastic and Reconstructive Surgery, Dongguk University College of Medicine, Gyeongju, Korea
,
Seok-Ju Yoo 
2   Department of Preventive Medicine, Dongguk University College of Medicine, Gyeongju, Korea
,
Hea-Kyeong Shin 
1   Department of Plastic and Reconstructive Surgery, Dongguk University College of Medicine, Gyeongju, Korea
› Institutsangaben
Funding None.
› Weitere Informationen
  Lizenzen und Reprints

Abstract

Background Basal cell carcinoma (BCC) is the most common type of nonmelanoma skin cancer. Typically, resection requires a safety margin of ≥4 mm. When removing tumor cells, achieving complete excision with minimal safety margins and reconstructing the defect to preserve the original appearance are important. In this study, we used a 3-mm resection margin to confirm recurrence and re-resection rates.

Methods Electronic medical records and photographic data were obtained for patients with primary BCC lesions less than 2 cm in diameter who underwent wide excision with a 3-mm surgical margin from January 2015 to November 2021. We analyzed factors determining recurrence and re-resection rates, such as tumor size, location, age, sex, underlying diseases (including immunosuppression state), ethnicity, subtypes, tumor borders, etc.

Results This study included 205 patients. The mean age and follow-up period were 73.0 ± 11.5 years and 10.2 ± 8.0 months, respectively. The recurrence and re-resection rates were 1.95% and 25.85%, respectively.

A statistically significant correlation was found between recurrence rate and tumor border (p = 0.013) and the re-resection rate was correlated statistically with location (p = 0.022) and immunosuppressed patients (p = 0.006).

Conclusion We found that a 3-mm excision margin provided sufficient safety in small facial BCC, resulting in ease of surgery and better aesthetic outcomes.

However, surgical margins must be determined case by case by integrating various patient factors. In particular, a surgical margin of ≥4 mm is required for BCC in high-risk areas, immunosuppressed patients, or poorly defined border.

Keywords

skin cancer - excision margins - basal cell carcinoma - surgical flap - skin graft

Authors' Contributions

Conceptualization: H.K.S.

Data curation: M.J.Y.

Formal analysis: S.J.Y. and H.K.S.

Writing - original draft: M.J.Y.

Writing - review & editing: H.K.S., M.J.Y.

All authors read and approved the final. manuscript.


Ethical Approval

The study was approved by the Institutional Review Board of Dongguk University Hospital (IRB No. 110757-202211-HR-02-02) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived because this study design is a retrospective chart review.


Patient Consent

The patients' legal guardian provided written informed consent for the publication and the use of patients' images.




Publikationsverlauf

Eingereicht: 12. Juli 2023

Angenommen: 28. Mai 2024

Accepted Manuscript online:
05. Juni 2024

Artikel online veröffentlicht:
06. August 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91 (01) 24-30
    CrossrefPubMedSuche in Google Scholar
  • 2 Mendez BM, Thornton JF. Current basal and squamous cell skin cancer management. Plast Reconstr Surg 2018; 142 (03) 373e-387e
    CrossrefPubMedSuche in Google Scholar
  • 3 Mohan SV, Chang AL. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep 2014; 3 (01) 40-45
    CrossrefPubMedSuche in Google Scholar
  • 4 Dummer R, Karpova MB, Barysch MJ. Basal cell carcinomas: molecular abnormalities and molecularly targeted therapies. Expert Rev Dermatol 2009; 4: 355-369
    CrossrefSuche in Google Scholar
  • 5 Gallagher RP, Hill GB, Bajdik CD. et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995; 131 (02) 157-163
    CrossrefPubMedSuche in Google Scholar
  • 6 Collins L, Quinn A, Stasko T. Skin cancer and immunosuppression. Dermatol Clin 2018; 37 (01) 83-94
    CrossrefPubMedSuche in Google Scholar
  • 7 Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6 (04) 295-307
    CrossrefPubMedSuche in Google Scholar
  • 8 Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 2013; 210 (11) 2435-2466
    CrossrefPubMedSuche in Google Scholar
  • 9 Acartürk TO, Edington H. Nonmelanoma skin cancer. Clin Plast Surg 2005; 32 (02) 237-248
    CrossrefPubMedSuche in Google Scholar
  • 10 Beer GM, Bermoser K, Kompatscher P. Closure of nasal defects after tumor excision with local flaps. Aesthetic Plast Surg 1998; 22 (01) 42-47
    CrossrefPubMedSuche in Google Scholar
  • 11 Bittner GC, Cerci FB, Kubo EM, Tolkachjov SN. Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations. An Bras Dermatol 2021; 96 (03) 263-277
    CrossrefPubMedSuche in Google Scholar
  • 12 Nahhas AF, Scarbrough CA, Trotter S. A review of the Global guidelines on surgical margins for nonmelanoma skin cancers. J Clin Aesthet Dermatol 2017; 10 (04) 37-46
    PubMedSuche in Google Scholar
  • 13 Ito T, Inatomi Y, Nagae K. et al. Narrow-margin excision is a safe, reliable treatment for well-defined, primary pigmented basal cell carcinoma: an analysis of 288 lesions in Japan. J Eur Acad Dermatol Venereol 2015; 29 (09) 1828-1831
    CrossrefPubMedSuche in Google Scholar
  • 14 Lin SH, Cheng YW, Yang YC, Ho JC, Lee CH. Treatment of pigmented basal cell carcinoma with 3 mm surgical margin in Asians. BioMed Res Int 2016; 2016: 7682917
    PubMedSuche in Google Scholar
  • 15 Ünverdi OF, Yücel S, Berk OS. Recommended surgical margins for basal cell carcinoma. Is 3 mm safe enough?. Adv Skin Wound Care 2020; 33 (04) 209-212
    CrossrefPubMedSuche in Google Scholar
  • 16 Quazi SJ, Aslam N, Saleem H, Rahman J, Khan S. Surgical margin of excision in basal cell carcinoma: a systematic review of literature. Cureus 2020; 12 (07) e9211
    PubMedSuche in Google Scholar
  • 17 Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013; 133 (05) 1188-1196
    CrossrefPubMedSuche in Google Scholar
  • 18 Omland SH, Nielsen PS, Gjerdrum LM, Gniadecki R. Immunosuppressive environment in basal cell carcinoma: the role of regulatory T cells. Acta Derm Venereol 2016; 96 (07) 917-921
    CrossrefPubMedSuche in Google Scholar
  • 19 Tomas S. Difficult to diagnose skin cancer–the ‘aggressive’ BCC. Aust Fam Physician 2009; 38 (07) 492-497
    PubMedSuche in Google Scholar
  • 20 Argenziano G, Soyer HP, Chimenti S. et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48 (05) 679-693
    CrossrefPubMedSuche in Google Scholar